GlassScriptPhysician profile
Maria V Devita
NPI 1184792996
$51,023.42
in general payments reported to CMS, 2019-2025
11 companies · $2,571 in 2025
The $2,571 reported for 2025 was more than what 91% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $308 · 2020: $2,550 · 2021: $2,750 · 2022: $19K · 2023: $13K · 2024: $11K · 2025: $2,571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $25K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,600 · Education: $184 · Food and Beverage: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $24,934.80 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,600.00 |
| Education | $183.98 |
| Food and Beverage | $164.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nuwellis, INC. | $50,386.64 | 2020-2025 | Aquadex Smartflow Console |
| Mallinckrodt Hospital Products INC. | $200.06 | 2024-2025 | Acthar |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $124.97 | 2019 | |
| Scpharmaceuticals INC. | $44.21 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $35.67 | 2019 | |
| Calliditas Therapeutics US INC. | $26.67 | 2025 | Tarpeyo |
| Vifor Pharma, INC. | $26.16 | 2023 | Korsuva |
| Amgen INC. | $21.91 | 2019 | |
| Fresenius USA Marketing, INC. | $20.42 | 2022 | |
| Lilly USA, LLC | $11.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Devita listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.